Journal
JOURNAL OF PHARMACEUTICAL SCIENCES
Volume 102, Issue 5, Pages 1404-1418Publisher
ELSEVIER SCIENCE INC
DOI: 10.1002/jps.23462
Keywords
genotoxic impurities; analytical chemistry; toxicology; regulatory science; in silico modeling; stability; degradation; control strategy; risk assessment; threshold of toxicological concern
Ask authors/readers for more resources
The strategies implemented at Eli Lilly and Company to address European Medicines Agency and US Food and Drug Administration requirements governing the control of genotoxic impurities (GTIs) are presented. These strategies were developed to provide understanding with regard to the risk and potential liabilities that could be associated with developmental and marketed compounds. The strategies systematize the assessment of impurities for genotoxic potential, addressing both actual and potential impurities. Timing of activities is designed to minimize impact to development timelines while building a data package sufficient to either discharge the risk of potential GTI formation or support the implementation of a specification necessary for long-term control. This article presents the background associated with GTI control, the types of impurities that should be assessed, and the actions to be taken when an impurity is found to be genotoxic. A systematic approach to define potential degradation products derived from stress-testing studies is outlined with a proposal to perform a genotoxic risk assessment on these impurities. Finally, an Arrhenius-based strategy is proposed for a rapid assessment of the likelihood of potential degradation impurities to form in the commercial drug product formulation. Importantly, this article makes a proposal for discharging the risk of a potential GTI with supporting data. (c) 2013 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 102:14041418, 2013
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available